The annual national conference of the American Diabetes Association (ADA) this week served as a pivotal platform for unveiling cutting-edge advancements in diabetes and obesity treatment, particularly within the burgeoning GLP-1 receptor agonist class. Pharmaceutical giants Eli Lilly, Novo Nordisk, AstraZeneca, and Pfizer presented a wealth of new clinical and preclinical data, highlighting significant progress in weight management, blood sugar control, and the treatment of associated comorbidities. However, the scientific revelations were juxtaposed against an unforeseen and dramatic turn of events, as several prominent researchers were escorted out by police after distributing an editorial critical of the then-current Trump administration’s science policies, casting a shadow of controversy over the proceedings.
A Conference of Dual Narratives: Innovation Meets Disruption
The ADA conference, a cornerstone event in the global diabetes community, typically draws thousands of clinicians, researchers, and industry professionals to share the latest research, foster collaboration, and shape future treatment guidelines. This year’s gathering, held from June 21-25, 2026, was no exception in its scientific output, featuring numerous presentations on novel therapeutic strategies and deeper insights into disease mechanisms. Yet, the incident involving the removal of esteemed scientists introduced an unusual and concerning element, prompting discussions about academic freedom, scientific advocacy, and the boundaries of expression within professional forums.
The controversy unfolded shortly before a scheduled address by Jay Bhattacharya, director of the National Institutes of Health (NIH). Researchers began distributing copies of an editorial titled “Misguided Brushes of a Pen Continue to Dismantle,” which had been published in Diabetes Care, the ADA’s flagship journal. The editorial meticulously detailed the adverse effects of federal funding cuts and other administrative actions on critical diabetes research, arguing that these policies threatened to undermine public health advancements and the scientific integrity of institutions like the NIH. This act of protest, occurring within the very halls dedicated to scientific discourse, quickly escalated.
According to Aaron Kelly, a professor of pediatrics at the University of Minnesota and one of the researchers involved, security staff initially requested the researchers to move outside and attempted to confiscate the papers. When the group later tried to re-enter the convention through another entrance, they were confronted by event security and police officers. Justin Ryder, another researcher present, recounted to The New York Times that they were informed any further attempt to enter the premises would constitute trespassing and lead to arrest. Subsequently, five of the researchers, some of whom were scheduled to present their own findings, were officially barred from participating further in the conference, a move that sparked significant debate among attendees and the wider scientific community.
The incident highlighted a growing tension between the scientific community’s role in public advocacy and the organizational control exercised by large professional bodies. While conference organizers are responsible for maintaining order and ensuring the smooth running of events, the decision to involve law enforcement in response to the distribution of a peer-reviewed editorial from the organization’s own journal raised questions about the appropriate limits of such interventions and the protection of free speech within scientific gatherings. The ADA has yet to issue a comprehensive public statement addressing the specifics of the police involvement, though implicit in the actions taken was a prioritization of maintaining the conference’s established order over allowing unsanctioned political expression within its venues.
The GLP-1 Revolution Continues: A Deep Dive into New Data
Despite the off-stage drama, the core focus of the ADA conference remained the advancement of diabetes and obesity research. The spotlight shone brightly on the latest generation of GLP-1 receptor agonists (GLP-1 RAs) and multi-agonists, which are rapidly reshaping the therapeutic landscape. GLP-1 RAs mimic the action of glucagon-like peptide-1, a natural hormone that stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety. The evolution of these drugs, from earlier daily injections to weekly formulations and now to multi-agonists and innovative delivery methods, represents a paradigm shift in managing these chronic conditions.
Eli Lilly’s Retatrutide: A Triple Threat for Broader Health Benefits
Eli Lilly presented compelling Phase 3 results for its investigational triple agonist, retatrutide, generating significant excitement. Retatrutide targets not only the GLP-1 receptor but also the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon receptor. This multi-pronged approach is hypothesized to offer enhanced efficacy in weight loss and metabolic control compared to single or dual agonists.
The data revealed unprecedented levels of body weight reduction, with participants on the highest dose experiencing an average of 28.3% body weight loss over 80 weeks. This figure surpasses the efficacy seen with existing single and dual agonists, positioning retatrutide as a potential leader in the severe obesity treatment space. Beyond weight, the drug demonstrated remarkable improvements in obesity-related complications. Knee osteoarthritis pain, a debilitating condition often exacerbated by excess weight, was reduced by up to 73.1%. Similarly, the severity of moderate-to-severe obstructive sleep apnea, another common comorbidity of obesity, decreased by 60.6%. These findings underscore the profound systemic impact of significant weight loss and the potential of retatrutide to address a spectrum of obesity-related health issues, moving beyond mere glycemic control.
Ania Jastreboff, the lead investigator for the trial, emphasized the broader implications, stating, “These findings demonstrate what may be possible when we treat obesity and impact overall health, and what this could mean for people living with obesity and its related complications.” For patients with type 2 diabetes, retatrutide also achieved substantial glycemic control, reducing A1C by up to 2%. Up to 90% of participants achieved an A1C below 7%, the general target recommended by the ADA. Furthermore, the drug improved key cardiometabolic markers, reducing triglycerides by up to 41%, non-HDL cholesterol by 24.2%, and systolic blood pressure by 12.3 mmHg.
The tolerability profile of retatrutide was generally consistent with other GLP-1 RAs, with common adverse effects including nausea, diarrhea, constipation, and vomiting. Approximately 14.2% of participants on the highest dose experienced upper respiratory tract infections. A notable observation was the limited occurrence of dysesthesia, a sensory disturbance, which has been seen to a limited extent with related drugs, warranting continued monitoring in broader use. Lilly’s successful demonstration of retatrutide’s efficacy across multiple metabolic and weight-related endpoints signals a new frontier in the treatment of complex metabolic diseases, potentially offering a more holistic approach to patient care.
Novo Nordisk’s CagriSema: Navigating a Competitive Landscape
Novo Nordisk, a long-standing leader in diabetes care, presented new Phase 3 data for CagriSema, a co-formulation combining cagrilintide (an amylin analog) and semaglutide (a GLP-1 receptor agonist). This dual-action therapy aims to leverage the synergistic effects of both hormones in regulating appetite, gastric emptying, and glucose metabolism. The "REIMAGINE" program trials demonstrated significant reductions in HbA1c and body weight compared to comparators.
Martin Holst Lange, executive vice president, chief scientific officer, and head of Research and Development at Novo Nordisk, highlighted the drug’s potential, stating, “With these findings, CagriSema has the potential to be the first amylin and GLP-1 combination therapy that addresses blood glucose control with reductions in bodyweight for people living with type 2 diabetes.” In a head-to-head comparison with semaglutide (Ozempic) alone, CagriSema achieved a greater reduction in both HbA1c and body weight. Specifically, the highest dose of CagriSema led to a 14.2% reduction in body weight, surpassing the 10.2% reduction observed with the same dose of semaglutide after 68 weeks.
However, the path for CagriSema in the highly competitive obesity market has not been without its challenges. Earlier this year, another Phase 3 trial indicated that CagriSema was inferior to Eli Lilly’s tirzepatide (Zepbound), a dual GLP-1/GIP agonist. In that trial, CagriSema achieved 23% weight loss over 84 weeks, while tirzepatide demonstrated 25.5% weight loss. Addressing this comparison in a call with investors, Martin Lange explained that Zepbound “performed unusually well on efficacy compared to what has typically been reported in most previous trials of a similar nature.” He further noted that in a separate Phase 3 trial involving adults with pre-diabetes and obesity, tirzepatide yielded an average weight reduction of 22.9% on its highest dose, a figure slightly lower than the 25.5% seen in the CagriSema comparator trial, suggesting variability in trial outcomes and potentially different patient populations or trial designs. Despite not surpassing tirzepatide, CagriSema’s robust performance against semaglutide alone and its unique dual mechanism provide Novo Nordisk with a strong contender in the evolving treatment landscape, potentially appealing to patients seeking alternatives or specific therapeutic profiles.
The Pursuit of Convenience: Oral and Monthly GLP-1s
The quest for more convenient dosing options continues to drive innovation in the GLP-1 space, with several companies developing oral and longer-acting injectable formulations. Oral GLP-1s, while offering the convenience of a pill, have historically faced challenges related to bioavailability and achieving the same level of efficacy as injectables.
AstraZeneca’s Elecoglipron: Advancing Oral Therapy
AstraZeneca presented promising results for its oral GLP-1, elecoglipron. The drug achieved an 11.8% weight reduction at 36 weeks and lowered HbA1c by 1.9% at 26 weeks, with 90% of patients reaching an HbA1c below 7%. These results are significant for an oral agent and position elecoglipron for advancement into Phase 3 trials for both obesity and type 2 diabetes. Importantly, these trials will also evaluate cardiovascular and kidney outcomes, reflecting the growing understanding of GLP-1 RAs’ protective effects beyond glycemic control. If successful, elecoglipron could offer a compelling oral option for patients hesitant about injectable therapies, broadening access to effective weight management and diabetes treatment.
Ascletis’ ASC30: Focusing on Tolerability
Chinese biopharmaceutical company Ascletis also showcased its oral GLP-1, ASC30, which demonstrated weight loss of up to 7.7% at week 13 in Phase 2 trials. A key differentiating factor highlighted was the drug’s tolerability profile, showing approximately half the rate of vomiting observed with orforglipron, another oral GLP-1 RA. Reducing gastrointestinal side effects is crucial for patient adherence and quality of life, potentially giving ASC30 an edge in the oral market. Additionally, Ascletis presented preclinical data for its oral amylin receptor agonist, ASC37, which showed selectivity for the human amylin type 1 receptor comparable to eloralintide, hinting at future combination therapies or standalone oral amylin options.
Pfizer’s Berobenatide: The Monthly Advantage
Pfizer, recognizing the demand for less frequent dosing, presented data on berobenatide, a once-monthly GLP-1 receptor agonist. This long-acting peptide achieved a 15.9% weight loss at 32 weeks and a 2.2% reduction in HbA1c at 18 weeks, demonstrating robust efficacy for a monthly formulation. Jim List, chief internal medicine officer at Pfizer, underscored the drug’s potential: “These data highlight the potential for berobenatide to be the first approved monthly GLP-1 RA peptide and support our extensive Phase 3 program that includes 10 studies for chronic weight management and obesity-related comorbidities.”
Pfizer’s commitment to this program is evident with the ongoing enrollment in the VESPER-6 Phase 3 study, which investigates monthly maintenance dosing for berobenatide in adults with obesity or overweight. Furthermore, the SOLIS-1 Phase 2b study is exploring weekly and monthly maintenance dosing of an ultra-long-acting amylin analog (PF-3945) both as a monotherapy and in combination with berobenatide. A monthly injection could significantly improve patient convenience and adherence compared to weekly or daily injections, offering a distinct advantage in a crowded market.
Broader Implications and Future Outlook
The 2026 ADA conference reinforced the transformative power of GLP-1-based therapies in managing type 2 diabetes and obesity, moving beyond simple glycemic control to address a cascade of associated health problems. The reported data from Eli Lilly, Novo Nordisk, AstraZeneca, and Pfizer illustrate a rapidly evolving landscape where companies are striving for enhanced efficacy, broader indications, and improved patient convenience through novel mechanisms and delivery methods.
The intensifying competition in this therapeutic area is a positive development for patients, promising a wider array of effective treatment options tailored to individual needs and preferences. The focus on reducing comorbidities like osteoarthritis pain and sleep apnea, alongside cardiovascular and kidney outcomes, signifies a holistic approach to patient health, potentially leading to significant improvements in quality of life and reduced healthcare burdens.
However, the incident involving the researcher removals serves as a stark reminder that scientific conferences are not isolated from broader societal and political currents. The editorial’s critique of science policy underscores the vital link between robust research funding and public health progress. As scientific advancements accelerate, the intersection of science, policy, and advocacy will likely become even more pronounced, prompting professional organizations to carefully consider their roles in facilitating open discourse while maintaining conference decorum.
Looking ahead, the next few years will undoubtedly witness the launch of several new GLP-1-based therapies, including multi-agonists and innovative oral and long-acting injectable formulations. The challenge will then shift to ensuring equitable access, managing rising healthcare costs, and integrating these powerful new tools into comprehensive patient care strategies. The ADA conference, despite its unexpected controversy, affirmed that the field of diabetes and obesity research is in a period of unprecedented innovation, with the potential to profoundly impact millions of lives worldwide.
